Navigation Links
Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
Date:2/5/2009

TORONTO, Feb. 5 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; PREMF.pk) today announced that its recently completed clinical trial data was presented at the 4th Annual Academic Surgical Congress in Fort Myers, FL. The peer reviewed data was presented by Dr. Anees B. Chagpar from the University of Louisville. The presentation entitled, "Quantitative Galactose Oxidase Schiff's reaction in Nipple Aspirate Fluid may distinguish women with or without Breast Cancer" concluded by stating that "GOS reactivity as measured by adjusted chroma values are significantly different between normal patients, those with Ductal Carcenoma In Situ and those with invasive cancer" and that "these results warrant further investigation".

"We are extremely pleased that the data was supportive of this novel breast cancer test and that the investigators feel that there is a need to continue to explore the potential of this test, and thus confirm that there is value to the technology. However, it is clear that funding to develop these potentially valuable tests is not readily available today and as such, work on this test will cease, at least for a while," said Dr. Brent Norton, President and CEO of PreMD Inc. "We are hopeful that one or more interested parties' steps forward to invest in or acquire this technology as it has the potential to advance the fight against this disease," he added.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include PREVU* POC and PREVU* LT, both non-invasive skin cholesterol tests. The Company's cancer tests include ColorectAlertTM, LungAlertTM and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


'/>"/>
SOURCE PreMD Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test ... Continue Reading ... New: ... , , bioLytical Laboratories (la "Compañía"), ... está expandiendo el lanzamiento de su INSTI HIV Self Test  a África con ...
(Date:12/2/2016)... North America held the largest share in the ... aged population and demand for remote monitoring ECG devices. On ... region is expected to witness the highest growth rate during ... Company (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... Netherlands ) and Mindray Medical International Limited ( ...
(Date:12/2/2016)... Research and Markets has announced the addition of the ... 2022" report to their offering. ... , The global ultrasound device ... expected to grow at a CAGR of 5.5% during 2016-2022. Based on ... the forecast period, a CAGR of 8.8% in the global market. Among ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has published ... Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. (After ... up exactly with Bible Prophecy – a protected way for those who will believe. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a ... applications, was named the best Sales Team of 2016 as part of the ... today by the Software & Information Industry Association (SIIA), the principal trade association ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... that they now offer a comprehensive in-house dental plan for all patients. Understanding ... developed a plan that gives patients a number of perks, including discounts on ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center ... has announced the opening of a new residential mental health treatment program in ... health issues such as severe anxiety, depression, bi-polar disorder, and other related issues. ...
Breaking Medicine News(10 mins):